Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
dalfampridine (ampyra) (1 trial)
corticotropin (acthar) (1 trial)
Ischemia (Phase 4)
Neuritis (Phase 1)
Optic Nerve Diseases (Phase 4)
Optic Neuritis (Phase 1)
Optic Neuropathy, Ischemic (Phase 4)
Trials (2 total)
Trial APIs (2 total)